– USA, MA – Exosome Diagnostics, the developer of a leading liquid biopsy platform that enables non-invasive diagnosis of disease states, potentially obviating the need for tissue biopsy, has announced the appointment of Dan Zabrowski PhD, as a member of its Board of Directors.
“I am delighted that Dan, a veteran dynamic leader in the pharmaceutical and diagnostic industry, has agreed to join the Board of Exosome Diagnostics,” stated Kapil Dhingra, Chairman of the Board of Directors of Exosome Diagnostics. Dr. Dhingra continued, “Dan’s impressive experience in both the diagnostics and the pharmaceutical space positions him to help the Board and the management team guide Exosome Diagnostics to its next inflection point, ushering in a new paradigm of non-invasive diagnostic tests which we believe can dramatically improve patient outcomes.”
Dan has served in senior leadership positions at Hoffmann-La Roche for the past 20 years. From 2012, Dan has been President and Director of Roche Diagnostics, leading the Roche life science, sequencing and tissue diagnostics businesses. In this role, he was responsible for developing and launching 45 products, as well as establishing an independent sequencing unit. From 2007 – 2012, he was Head of Roche Pharma Partnering. Under his leadership, the group executed over 280 agreements for product and technology licensing, acquisitions and divestments. In addition, he has a wealth of experience in pharmaceutical development, including operations and regulatory affairs.
“I am thrilled to join the Board of Exosome Diagnostics, a leading company in the liquid biopsy space. Medicine is rapidly moving to a paradigm of personalized medicine. The ability to extract mRNA and cfDNA from blood, in one step, offers a differentiated proposition to enable personalized medicine. I look forward to working with my fellow Board members and the management team as we seek to develop and commercialize meaningful solutions for patients with serious illnesses such as cancer and other disease states that cannot readily be addressed by tissue biopsy.”
About Exosome Diagnostics
Exosome Diagnostics is a privately held company focused on developing and commercializing revolutionary biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. The company’s novel exosome-based technology platform, ExoLution™, can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
